# Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is an Asset Manager based in Tarrytown, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Tarrytown, United States
- **Region:** North America
- **Address:** Tarrytown, NY, United States
- **Founded:** 1988
- **Assets under management:** Undisclosed
- **Website:** www.regeneron.com
- **LinkedIn:** https://www.linkedin.com/company/regeneron-pharmaceuticals

## Regulatory record

- **Reports private funds:** No

## About

Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

## Sectors

- Biotechnology
- Genetic Medicines

## Offices

- Sleepy Hollow, NY
- Rensselaer, NY
- Uxbridge, UK
- Dublin, Ireland
- Tokyo, Japan

## People

- Leonard S. Schleifer — Co-Founder, President and Chief Executive Officer
- George D. Yancopoulos — Co-Founder, President and Chief Scientific Officer

## Questions

### Who makes the major capital-allocation decisions at Regeneron?

Capital allocation is driven by the co-founders: CEO Leonard Schleifer sets the strategic direction, while President and Chief Scientific Officer George Yancopoulos oversees the research pipeline. Major R&D and partnership commitments are authorized by the board, but the company’s science-forward posture means Yancopoulos’s team effectively decides which drug candidates advance.

### How does Regeneron screen new drug candidates without a typical investor-led model?

Regeneron’s pipeline originates almost entirely from its own target-discovery work. The Regeneron Genetics Center has sequenced over 3 million exomes, linking genetic variants to disease phenotypes. Targets identified there are fed into the VelociSuite technology platform to produce fully human antibodies, a process that systematically generates candidates for clinical testing.

### Does Regeneron function like a venture capital firm by spinning out portfolio companies?

No. It operates as a fully integrated pharmaceutical company. It does not raise outside funds, charge management fees, or syndicate risk through VC-style spinouts. Instead, it self-funds R&D from commercial revenues and co-development agreements, most notably the global partnership with Sanofi on Dupixent.

### What therapeutic areas does Regeneron avoid?

Regeneron does not publicly declare strict sector exclusions. Its current pipeline focuses on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, and infectious diseases. It has not disclosed active programs in areas such as reproductive health or consumer medical devices.

## Related profiles

- [Illumina Ventures](https://altss.com/profile/illumina)
- [Palm Peak Capital](https://altss.com/profile/palm-peak-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/regeneron-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology